Edition:
United Kingdom

Seikagaku Corp (4548.T)

4548.T on Tokyo Stock Exchange

1,597JPY
13 Nov 2018
Change (% chg)

¥-19 (-1.18%)
Prev Close
¥1,616
Open
¥1,601
Day's High
¥1,602
Day's Low
¥1,569
Volume
55,600
Avg. Vol
85,120
52-wk High
¥2,236
52-wk Low
¥1,383

Latest Key Developments (Source: Significant Developments)

Seikagaku says clinical trial for SI-449
Monday, 21 May 2018 

May 21 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a clinical trial (pilot study) in Japan for SI-449, an adhesion barrier for use in surgery .  Full Article

Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan
Friday, 23 Mar 2018 

March 23(Reuters) - Seikagaku Corp <4548.T>:Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation.  Full Article

Ribomic signs collaborative research contract with SEIKAGAKU
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ribomic Inc <4591.T>:Says it signed collaborative research contract with SEIKAGAKU CORPORATION <<<4548.T>>>.Says two entities mainly cooperate on new technologies development of drug discovery related to Aptamers.  Full Article

Seikagaku initiates phase II study of SI-613 for treatment of knee osteoarthritis in U.S.
Friday, 16 Jun 2017 

June 16(Reuters) - Seikagaku Corp <4548.T>:Says it announces the start of phase II study of SI-613 in patients with osteoarthritis of the knee, in the U.S. .  Full Article

Ono Pharmaceutical signs co-development and marketing collaboration agreement with Seikagaku
Friday, 12 May 2017 

May 12(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says Seikagaku Corp <<<4548.T>>> and Ono Pharmaceutical Co., Ltd. have reached a basic agreement related to.co-development and marketing collaboration on SI-613 under development by Seikagaku for the treatment of osteoarthritis in Japan.  Full Article

Seikagaku initiates phase III study of SI-613
Friday, 3 Feb 2017 

Seikagaku Corp <4548.T> :Says co announces the start of Phase III study of SI-613, a joint improving agent indicated for treatment of osteoarthritis, in Japan.  Full Article